← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Terlipressin

FDA approved · Rx

Vasopressin receptor agonist

Also known as: Terlivaz, glypressin, glycylpressin, Terlipressine, Terlipressina, Terlipressinum, Terlipresina, Variquel

Evidence score
95/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 115 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Terlipressin is a synthetic analog of vasopressin, sold in the United States under the brand name Terlivaz. It acts mainly on V1 vasopressin receptors, constricting blood vessels in the gut region and helping redirect blood flow, which is thought to improve blood flow to the kidneys in certain liver conditions.

What the evidence shows

Automatic summaryHuman trials

Terlivaz is FDA-approved for improving kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function, supported by over 100 registered human trials and a large published literature. Other uses studied in trials, such as variceal bleeding or septic shock, are not FDA-approved indications in the United States.

Key facts

Molecular formula
C52H74N16O15S2
Molecular weight
1227.4 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

115registered studies
Phase 4most advanced phase
48completed (sample)
3recruiting (sample)

Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1

Phase 3CompletedNCT02770716

Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome

Phase 2Active Not RecruitingNCT06256432

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

Phase 2UnknownNCT05875948

Early Use of TIPSS in Patients With Cirrhosis and Variceal Bleeding

CompletedNCT02377141

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

1,195papers referencing Terlipressin

A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.

Gastroenterology2008

Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.

Gastroenterology2008

Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.

Hepatology2002

Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.

N Engl J Med2021

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.